Insulin signaling and amphetamines

Abuse of psychostimulants such as amphetamine remains a serious public health concern.

Amphetamines mediate their behavioral effects by stimulating dopaminergic signaling throughout reward circuits of the brain.

This property of amphetamine relies on its actions at the dopamine transporter (DAT), a presynaptic plasma membrane protein responsible for the reuptake of extracellular dopamine.

Recently, researchers have revealed the novel ability of insulin signaling pathways in the brain to regulate DAT function as well as the cellular and behavioral actions of amphetamine.

In a new study published in the open-access journal PLoS Biology, Aurelio Galli, Jason Williams and colleagues used a model of Type I diabetes in rats to uncover how insulin signaling regulates DAT-mediated amphetamine effects.

They show that by depleting insulin, or through selective inhibition of insulin signaling, they can severely attenuate amphetamine-induced dopamine release and impair DAT function.

This study verifies in vivo that insulin signaling can dynamically influence the neuronal effects of amphetamine-like psychostimulants. Therefore, the insulin signaling pathway, through its unique regulation of brain dopamine, may be targeted for the treatment of amphetamine abuse.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Elevated insulin resistance, advanced cell aging associated with childhood poverty